🇺🇸 BMRN — BioMarin Pharmaceutical Inc.

Salud Compra
← Volver

Precio actual

56,03 USD

Máx. histórico

149,13

4127 días

Caída desde máximo

-62,43%

Rango 52 semanas

49,26 – 70,98

Variación hoy

-0,16%

Cierre anterior

56,12

Rango de hoy

55,00 – 56,08

Volumen hoy

2.733.184

Peor caída histórica

-90,58%

01/03/2000 → 27/08/2002

Recuperado en 1960 días

Volatilidad anualizada ⓘ

49,10%

Información
Nombre completo
BioMarin Pharmaceutical Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
3.221
PER ⓘ
150,43 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
91,04 USD (puede no estar actualizado)
Primera cotización
26/07/1999
Precio actualizado
hace 7 horas
Sobre la empresa

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
09/12/2016 84,67 87,52 82,58 82,68 -0,99% 5,83% 1.843.200
08/12/2016 81,70 83,72 80,50 83,51 +3,07% 3,94% 1.135.200
07/12/2016 81,36 82,34 79,50 81,02 -2,37% 3,49% 1.814.500
06/12/2016 82,99 83,48 81,89 82,99 +0,65% 1,92% 1.393.600
05/12/2016 82,51 84,59 81,86 82,45 +0,29% 3,31% 1.702.100
02/12/2016 83,39 84,02 81,89 82,21 -1,34% 2,55% 1.142.500
01/12/2016 85,97 86,46 82,51 83,33 -2,69% 4,59% 1.194.600
30/11/2016 86,64 87,90 85,53 85,63 -1,23% 2,74% 1.471.500
29/11/2016 87,46 88,00 85,86 86,70 -1,88% 2,45% 1.116.300
28/11/2016 89,00 89,10 87,01 88,36 -0,72% 2,35% 1.388.600
25/11/2016 88,06 89,10 86,52 89,00 +1,02% 2,93% 647.500
23/11/2016 84,59 88,39 83,62 88,10 +3,13% 5,64% 1.299.100
22/11/2016 87,51 88,30 84,42 85,43 -2,37% 4,43% 1.047.000
21/11/2016 89,13 89,99 86,74 87,50 -1,69% 3,65% 1.132.400
18/11/2016 90,42 91,21 88,92 89,00 -1,92% 2,53% 824.700
17/11/2016 89,15 92,30 88,70 90,74 +1,50% 4,04% 1.120.100
16/11/2016 91,61 92,31 89,31 89,40 -3,05% 3,27% 935.100
15/11/2016 91,93 92,65 89,40 92,21 -0,75% 3,54% 1.167.100
14/11/2016 91,78 93,85 90,13 92,91 +1,59% 4,05% 1.620.400
11/11/2016 93,28 93,28 90,12 91,46 -2,22% 3,39% 1.243.400
10/11/2016 92,80 95,56 91,46 93,54 +1,86% 4,42% 2.166.200
09/11/2016 89,00 98,34 88,52 91,83 +10,07% 11,03% 3.871.600
08/11/2016 82,79 84,46 82,12 83,43 -0,13% 2,83% 1.240.200
07/11/2016 82,64 84,07 81,64 83,54 +1,88% 2,94% 1.882.700
04/11/2016 79,65 84,59 78,75 82,00 +4,30% 7,33% 2.099.000
03/11/2016 81,43 81,43 78,42 78,62 -2,82% 3,70% 1.471.800
02/11/2016 82,38 82,71 80,77 80,90 -2,19% 2,35% 1.223.700
01/11/2016 80,30 82,88 79,31 82,71 +2,72% 4,45% 1.182.100
31/10/2016 81,26 81,26 80,00 80,52 -0,75% 1,55% 1.139.300
28/10/2016 79,73 83,32 78,56 81,13 +0,14% 5,97% 1.923.000